Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates
Portfolio Pulse from
Supernus Pharmaceuticals (SUPN) reported Q4 earnings of $0.75 per share, surpassing the Zacks Consensus Estimate of $0.52. This marks a significant increase from $0.02 per share a year ago.
February 26, 2025 | 12:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Supernus Pharmaceuticals reported Q4 earnings of $0.75 per share, exceeding expectations and showing a significant increase from last year's $0.02 per share.
The significant earnings beat and year-over-year growth are likely to positively impact SUPN's stock price in the short term as it indicates strong financial performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100